GlassScriptPhysician profile
Hadi Berry
NPI 1316067895
$2,981.68
in general payments reported to CMS, 2019-2025
28 companies · $602 in 2025
The $602 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $361 · 2021: $380 · 2022: $276 · 2023: $367 · 2024: $543 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $384.67 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $382.60 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $282.11 | 2020-2024 | Repatha, Otezla |
| Lilly USA, LLC | $256.85 | 2019-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $244.48 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.77 | 2020-2025 | Jardiance |
| Pfizer INC. | $223.28 | 2019-2025 | |
| Amarin Pharma, INC. | $137.84 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $130.00 | 2023 | Libtayo |
| Axsome Therapeutics, INC. | $110.88 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $101.16 | 2020-2025 | Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.40 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $70.35 | 2020-2023 | |
| Abbvie INC. | $61.68 | 2021-2024 | |
| Indivior INC. | $34.15 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $28.17 | 2024 | Vivitrol |
| Dexcom, INC. | $24.07 | 2021 | |
| Akcea Therapeutics, INC. | $21.75 | 2019 | |
| Calliditas Therapeutics US INC. | $21.50 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.90 | 2024 | Austedo Xr |
| Merz North America, INC. | $18.81 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.64 | 2022 | |
| Bioventus LLC | $17.55 | 2019 | |
| Verona Pharma, INC. | $14.84 | 2025 | Ohtuvayre |
| Ibsa Pharma INC. | $13.87 | 2022 | |
| Gilead Sciences, INC. | $12.84 | 2021 | |
| Orexo US, INC. | $12.42 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hadi Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.